09/28/23 9:00 AMNasdaq : LXRX conferencesclinical trialLexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023Lexicon Pharmaceuticals,RHEA-AInegative
09/26/23 9:00 AMNasdaq : LXRX conferencesLexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announcedRHEA-AInegative
09/07/23 4:30 PMNasdaq : LXRX conferencesLexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment ConferenceLexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25 th Annual Global Investment Conference, taking place September 11-13, 2023. Jeffrey L. Wade, Lexicon’s president and chiefRHEA-AIneutral
09/07/23 9:00 AMNasdaq : LXRX Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase 2b dose optimization study planning underway, with initiation of dosing expected before the end of 2023, and extension to run in parallel with next-stageRHEA-AIpositive
08/21/23 9:00 AMNasdaq : LXRX conferencesclinical trialLexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug for heartRHEA-AInegative
08/08/23 9:00 AMNasdaq : LXRX clinical trialPublished Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart FailurePost-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of Approximately 50% Demonstrated for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days FollowingRHEA-AInegative
08/03/23 4:01 PMNasdaq : LXRX earningsLexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateINPEFA TM (sotagliflozin) receives FDA approval for the treatment of heart failure INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes LX9211 moving into late-stage development for the treatment ofRHEA-AIneutral
07/28/23 4:01 PMNasdaq : LXRX conferencesearningsLexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial results on Thursday, August 3 rd, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m.RHEA-AIneutral
07/28/23 8:00 AMNasdaq : LXRX managementLexicon Elects Diane E. Sullivan to Board of Directors Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diane E. Sullivan has been elected to its BoardRHEA-AIneutral
06/23/23 8:45 PMNasdaq : LXRX Lexicon Announces Planned Advancement of LX9211 Into Late-Stage DevelopmentFirst late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase 3 studies Feedback obtained from U.S. Food and Drug Administration (FDA) Conference Call and Webcast on Monday, June 26, 2023, at 8:00 am Eastern Time THE WOODLANDS, Texas,RHEA-AIvery positive